Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.74
AMAG's Cash to Debt is ranked lower than
83% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. AMAG: 0.74 )
Ranked among companies with meaningful Cash to Debt only.
AMAG' s 10-Year Cash to Debt Range
Min: 0.29  Med: 10000.00 Max: No Debt
Current: 0.74
Equity to Asset 0.41
AMAG's Equity to Asset is ranked lower than
77% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AMAG: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
AMAG' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.75 Max: 0.98
Current: 0.41
0.33
0.98
F-Score: 5
Z-Score: 1.50
M-Score: 5.17
WACC vs ROIC
5.68%
23.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.04
AMAG's Operating margin (%) is ranked higher than
85% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. AMAG: 16.04 )
Ranked among companies with meaningful Operating margin (%) only.
AMAG' s 10-Year Operating margin (%) Range
Min: -18217.46  Med: -130.08 Max: 8.03
Current: 16.04
-18217.46
8.03
Net-margin (%) 80.71
AMAG's Net-margin (%) is ranked higher than
98% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. AMAG: 80.71 )
Ranked among companies with meaningful Net-margin (%) only.
AMAG' s 10-Year Net-margin (%) Range
Min: -15420.63  Med: -124.17 Max: 109.19
Current: 80.71
-15420.63
109.19
ROE (%) 45.50
AMAG's ROE (%) is ranked higher than
97% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. AMAG: 45.50 )
Ranked among companies with meaningful ROE (%) only.
AMAG' s 10-Year ROE (%) Range
Min: -86.79  Med: -21.78 Max: 42.96
Current: 45.5
-86.79
42.96
ROA (%) 17.89
AMAG's ROA (%) is ranked higher than
95% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. AMAG: 17.89 )
Ranked among companies with meaningful ROA (%) only.
AMAG' s 10-Year ROA (%) Range
Min: -67.05  Med: -16.91 Max: 16.42
Current: 17.89
-67.05
16.42
ROC (Joel Greenblatt) (%) 393.78
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. AMAG: 393.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1009.91  Med: -278.72 Max: 12.16
Current: 393.78
-1009.91
12.16
Revenue Growth (3Y)(%) 19.50
AMAG's Revenue Growth (3Y)(%) is ranked higher than
77% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AMAG: 19.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMAG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -31.2  Med: 11.00 Max: 265.9
Current: 19.5
-31.2
265.9
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AMAG Guru Trades in Q2 2014

Jim Simons 129,060 sh (+3.12%)
Paul Tudor Jones Sold Out
» More
Q3 2014

AMAG Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

AMAG Guru Trades in Q4 2014

Paul Tudor Jones 8,431 sh (New)
Ken Heebner 522,000 sh (New)
» More
Q1 2015

AMAG Guru Trades in Q1 2015

Paul Tudor Jones 38,762 sh (+359.76%)
Ken Heebner 522,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 15.80
AMAG's P/E(ttm) is ranked higher than
82% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 40.90 vs. AMAG: 15.80 )
Ranked among companies with meaningful P/E(ttm) only.
AMAG' s 10-Year P/E(ttm) Range
Min: 10.74  Med: 12.55 Max: 16.09
Current: 15.8
10.74
16.09
Forward P/E 9.23
AMAG's Forward P/E is ranked higher than
91% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 23.87 vs. AMAG: 9.23 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.00
AMAG's PE(NRI) is ranked higher than
83% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 39.90 vs. AMAG: 16.00 )
Ranked among companies with meaningful PE(NRI) only.
AMAG' s 10-Year PE(NRI) Range
Min: 10.73  Med: 12.54 Max: 16.26
Current: 16
10.73
16.26
P/B 3.21
AMAG's P/B is ranked higher than
65% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. AMAG: 3.21 )
Ranked among companies with meaningful P/B only.
AMAG' s 10-Year P/B Range
Min: 1.12  Med: 2.87 Max: 18.97
Current: 3.21
1.12
18.97
P/S 11.61
AMAG's P/S is ranked higher than
50% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. AMAG: 11.61 )
Ranked among companies with meaningful P/S only.
AMAG' s 10-Year P/S Range
Min: 3.62  Med: 20.68 Max: 496.73
Current: 11.61
3.62
496.73
PFCF 49.63
AMAG's PFCF is ranked lower than
56% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 41.97 vs. AMAG: 49.63 )
Ranked among companies with meaningful PFCF only.
AMAG' s 10-Year PFCF Range
Min: 36.32  Med: 49.63 Max: 351.64
Current: 49.63
36.32
351.64
POCF 49.63
AMAG's POCF is ranked lower than
63% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 34.67 vs. AMAG: 49.63 )
Ranked among companies with meaningful POCF only.
AMAG' s 10-Year POCF Range
Min: 36.32  Med: 67.97 Max: 1268.5
Current: 49.63
36.32
1268.5
EV-to-EBIT 71.55
AMAG's EV-to-EBIT is ranked lower than
76% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. AMAG: 71.55 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s 10-Year EV-to-EBIT Range
Min: -542.7  Med: -7.20 Max: 92.5
Current: 71.55
-542.7
92.5
Current Ratio 3.12
AMAG's Current Ratio is ranked lower than
61% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. AMAG: 3.12 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s 10-Year Current Ratio Range
Min: 1.65  Med: 8.39 Max: 54.4
Current: 3.12
1.65
54.4
Quick Ratio 2.90
AMAG's Quick Ratio is ranked lower than
60% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AMAG: 2.90 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s 10-Year Quick Ratio Range
Min: 1.4  Med: 8.06 Max: 54.33
Current: 2.9
1.4
54.33
Days Inventory 263.41
AMAG's Days Inventory is ranked lower than
84% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 116.21 vs. AMAG: 263.41 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s 10-Year Days Inventory Range
Min: 6.05  Med: 430.02 Max: 14478.33
Current: 263.41
6.05
14478.33
Days Sales Outstanding 106.21
AMAG's Days Sales Outstanding is ranked lower than
77% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. AMAG: 106.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s 10-Year Days Sales Outstanding Range
Min: 4.86  Med: 31.89 Max: 863.25
Current: 106.21
4.86
863.25

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 7.77
AMAG's Price/Projected FCF is ranked lower than
66% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 4.29 vs. AMAG: 7.77 )
Ranked among companies with meaningful Price/Projected FCF only.
AMAG' s 10-Year Price/Projected FCF Range
Min: 6.03  Med: 10.72 Max: 96.83
Current: 7.77
6.03
96.83
Price/Median PS Value 0.54
AMAG's Price/Median PS Value is ranked higher than
86% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. AMAG: 0.54 )
Ranked among companies with meaningful Price/Median PS Value only.
AMAG' s 10-Year Price/Median PS Value Range
Min: 0.15  Med: 0.76 Max: 79.17
Current: 0.54
0.15
79.17
Earnings Yield (Greenblatt) (%) 1.40
AMAG's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. AMAG: 1.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMAG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 1.30 Max: 1.5
Current: 1.4
1.1
1.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsource a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to extensive additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG Down on Cord Blood Registry Deal for $700 Million - Analyst Blog Jun 30 2015
With two acquisitions in the past year, Waltham's Amag still isn't done Jun 30 2015
AMAG Pharma Acquiring Stem-Cell Bank For $700 Million Jun 29 2015
AMAG buying Cord Blood Registries for $700 million Jun 29 2015
AMAG buying Cord Blood Registries for $700 million Jun 29 2015
AMAG Pharmaceuticals to Acquire Cord Blood Registry Jun 29 2015
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Jun 29 2015
AMAG Pharmaceuticals to Acquire Cord Blood Registry Jun 29 2015
AMAG Pharmaceuticals to Buy Stem Cell Company for $700 Million Jun 29 2015
On the heels of one major acquisition, Amag's CEO is on the hunt for another Jun 16 2015
Edited Transcript of AMAG presentation 11-Jun-15 7:25pm GMT Jun 13 2015
Coverage initiated on AMAG Pharma by Deutsche Bank Jun 12 2015
AMAG Pharmaceuticals Appoints Aaron Pelta as Vice President of Business Development Jun 09 2015
AMAG Pharmaceuticals Appoints Aaron Pelta as Vice President of Business Development Jun 09 2015
AMAG Pharmaceuticals Launches Initiative to Raise Awareness of Preterm Birth and the Importance of a... Jun 09 2015
AMAG Pharmaceuticals Launches Initiative to Raise Awareness of Preterm Birth and the Importance of a... Jun 09 2015
AMAG Pharmaceuticals, Inc. to Participate in the Barclays High Yield Bond and Syndicated Loan... Jun 05 2015
AMAG Pharmaceuticals, Inc. to Participate in the Barclays High Yield Bond and Syndicated Loan... Jun 05 2015
AMAG Pharmaceuticals Announces New Senior Management Appointments Jun 02 2015
AMAG Pharmaceuticals Announces New Senior Management Appointments Jun 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK